Henagliflozin

ApprovedSmall molecule

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Henagliflozin is one of 247 small molecule programs targeting Myocardial fibrosis. It is currently in Approved.

Indications

Total Trials

Active Trials

246

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial FibrosisActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

Diabetic NephropathyActive, not recruiting

FibrosisActive, not recruiting

Myocardial InfarctionActive, not recruiting

Weight LossActive, not recruiting

Type 2 DiabetesActive, not recruiting

Myocardial FibrosisPreclinical

Active, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Non-Alcoholic Fatty Liver DiseaseApproved

Active, not recruiting

Diabetic NephropathyPreclinical

Active, not recruiting

FibrosisApproved

Active, not recruiting

Myocardial InfarctionApproved

Active, not recruiting

Weight LossApproved

Active, not recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

Glargine

Eli Lilly

Preclinical

8 5

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

Forxiga

AstraZeneca

Preclinical

3 7

Lovaza

AstraZeneca

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

1 10

GLP-1

RRigshospitalet, Denmark

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Weight Loss

NCT06216340

Post-ApprovalNot yet recruiting

Fibrosis

NCT06762223

Q4 2027

Post-ApprovalNot yet recruiting

Prediabetes

NCT06448130

Q4 2028

N/ANot yet recruiting

Myocardial Fibrosis

NCT07294495

Clinical

Trials by Indication[1]

Myocardial Infarction1 trial

Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction

Completed·QQian geng·Phase 4·NCT06187727·248 enrolled

Cognitive impairment1 trial

Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial

Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT06085703·24 enrolled

Diabetic Nephropathy1 trial

Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis

Unknown status·QQianfoshan Hospital·N/A·NCT06031389·120 enrolled

Weight loss1 trial

Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes

Not yet recruiting·TThe First People's Hospital of Changzhou·Phase 4·NCT06216340·300 enrolled

Metformin1 trial

The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics

Unknown status·RRenJi Hospital·N/A·NCT06059287·64 enrolled

6 more indications

Myocardial fibrosis1 trial

Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR

Not yet recruiting·SShanghai East Hospital·N/A·NCT07294495·150 enrolled

Type 2 Diabetes1 trial

Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05742230·1,932 enrolled

Fibrosis1 trial

Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM

Not yet recruiting·XXiqiao Zhou·Phase 4·NCT06762223·190 enrolled

PreDiabetes1 trial

Henagliflozin's Impact on Prediabetes Remission

Not yet recruiting·SShandong Provincial Hospital·Phase 4·NCT06448130·984 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease

Unknown status·SSir Run Run Shaw Hospital·Phase 4·NCT06218342·156 enrolled

Infusion1 trial

Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

Completed·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT05677334·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Henagliflozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Henagliflozin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Henagliflozin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Henagliflozin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Trials by Indication[1]

Myocardial Infarction1 trial

Cognitive impairment1 trial

Diabetic Nephropathy1 trial

Weight loss1 trial

Metformin1 trial

Myocardial fibrosis1 trial

Type 2 Diabetes1 trial

Fibrosis1 trial

PreDiabetes1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Infusion1 trial

References

Drug Info

Quick Facts

Related News